Seaport Therapeutics, Inc SPTX
- Market cap
- $1.1B
- P/E
- 0.0×
Follow SPTX
Target Price Range
Analyst price targets
Free account| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | — | — | — | — | — | — | — | — | — |
Analyst estimates 2026–2028 Powerpack |
Low Price | ||
| — | — | — | — | — | — | — | — | — | — | High Price | |||
| — | — | — | — | — | — | — | — | — | 58 |
Employees
|
|||
| — | — | — | — | — | — | — | — | — | 0 |
Revenue/Emp
|
|||
| — | — | — | — | — | — | — | — | — | — | Revenue | |||
| — | — | — | — | — | — | — | — | — | — | Gross Margin | |||
| — | — | — | — | — | — | — | — | (47) | (74) |
EBT
|
|||
| — | — | — | — | — | — | — | — | 0.00% | 0.00% |
EBT Margin
|
|||
| — | — | — | — | — | — | — | — | (47) | (75) |
Net Income
|
|||
| — | — | — | — | — | — | — | — | 0 | (2) |
Depreciation
|
|||
| — | — | — | — | — | — | — | — | 0.00 | 0.00 |
Revenue/Sh
|
|||
| — | — | — | — | — | — | — | — | (49.72) | (31.54) |
Earnings/Sh
|
|||
| — | — | — | — | — | — | — | — | (31.42) | (32.83) |
Cash Flow/Sh
|
|||
| — | — | — | — | — | — | — | — | (0.12) | (0.15) |
Capex/Sh
|
|||
| — | — | — | — | — | — | — | — | (31.54) | (32.98) |
Free CF/Sh
|
|||
| — | — | — | — | — | — | — | — | 318.64 | 98.06 |
Book Value/Sh
|
|||
| — | — | — | — | — | — | — | — | 1 | 2 |
Shares
|
|||
| — | — | — | — | — | — | — | — | — | — | PE Ratio | |||
| — | — | — | — | — | — | — | — | — | — | PS Ratio | |||
| — | — | — | — | — | — | — | — | — | — | PB Ratio | |||
| — | — | — | — | — | — | — | — | — | — | EV/Sales | |||
| — | — | — | — | — | — | — | — | — | — | EV/FCF | |||
| — | — | — | — | — | — | — | — | (30) | (78) |
Op' Cash Flow
|
|||
| — | — | — | — | — | — | — | — | 0 | 0 |
Capex
|
|||
| — | — | — | — | — | — | — | — | (30) | (78) |
FCF
|
|||
| — | — | — | — | — | — | — | — | 299 | 210 |
Working Cap'
|
|||
| — | — | — | — | — | — | — | — | 0 | 0 |
Total Debt
|
|||
| — | — | — | — | — | — | — | — | (309) | (216) |
Net Debt
|
|||
| — | — | — | — | — | — | — | — | 300 | 233 |
Sh' Equity
|
|||
| — | — | — | — | — | — | — | — | 0.00% | (26.52%) |
ROA
|
|||
| — | — | — | — | — | — | — | — | 0.00% | (324.62%) |
ROIC
|
|||
| — | — | — | — | — | — | — | — | 0.00% | 127.57% |
ROE
|
|||
Seaport Therapeutics, Inc (SPTX) key facts
- Seaport Therapeutics, Inc reported a net loss of $74.9 million, or a loss of $31.54 per share, for fiscal 2025.
- As of September 25, 2026, SPTX traded at $21.52, a market capitalization of $1.1 billion.
- Return on equity was 127.6% and debt-to-equity 0.00.
Seaport Therapeutics, Inc (SPTX) Latest News
22 Sep
PureTech Health ended H1 2026 with $220 million in cash, funding runway to 2028. Seaport Therapeutics completed a $260 million NASDAQ IPO, validating the hub-and-spoke model and providing external capital. Gallup Oncology’s LYT200 received FDA Fast Track for relapsed/refractory high-risk MDS and cleared an End of Phase 1 meeting, paving the path to Phase 2 and external financing. The innovation engine remains active, targeting at least three concept-stage programs per year, with new candidates expected in H1 2027. PureTech reiterated capital discipline and plans to return cash to shareholders, guiding go-forward cash burn to $30–$40 million annually from about $90 million when late-stage programs were internal. Sealea has one asset in pivotal Phase 3 and will need additional funding; PureTech reserved about $70 million for Sealea and expects roughly $50 million in royalties/milestones from Cobenfy. STRIDE MDS is mutation-agnostic, with a 30–33 month timeline, and additional programs are in development. Seaport’s $260 million NASDAQ IPO validates the hub-and-spoke model and provides external capital, materially improving funding prospects and investor sentiment around PureTech’s ecosystem and SPTX prospects.
9 Sep
Seaport Therapeutics reports positive topline results from Phase 1 driving simulation trial of GlyphAllo in healthy volunteers. Positive Phase 1 trial data advances GlyphAllo development and strengthens pipeline prospects.
Seaport Therapeutics announced positive topline results from its Phase 1 driving simulation trial of GlyphAllo in healthy volunteers. Positive Phase 1 results advance GlyphAllo development and may support near-term investor sentiment at Seaport Therapeutics.
20 Aug
Seaport Therapeutics completes IPO with major pharma firms including Bristol Myers and Johnson & Johnson monitoring its progress. Interest from leading pharmaceutical companies after IPO signals major strategic opportunities and market momentum for Seaport.
3 Aug
Seaport Therapeutics reported second quarter 2026 financial results and highlighted recent corporate and clinical progress. Quarterly results combined with clinical updates produce moderate effects on near-term sentiment and operations.
9 Jun
Seaport Therapeutics reported positive multiple-ascending dose data from its Phase 1 proof-of-concept trial of GlyphAgo™ in healthy volunteers. Positive Phase 1 data supports pipeline progress but remains early-stage with limited immediate effects on operations or market position.
8 Jun
Seaport Therapeutics reported first quarter 2026 financial results and provided updates on recent corporate developments and clinical progress. Quarterly results with clinical updates offer moderate visibility into operations and pipeline but rarely shift long-term trajectory alone.
Seaport Therapeutics reported positive multiple-ascending dose data from its Phase 1 proof-of-concept trial of GlyphAgo™ in healthy volunteers. Positive Phase 1 data for GlyphAgo™ advances Seaport's drug development pipeline.